Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)

BACKGROUND. First‐line treatment for metastatic colorectal cancer (mCRC) typically entails a biologic such as bevacizumab (BEV) with 5‐fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5‐fluorouracil/leucovorin/irinotecan (FOLFIRI). STEAM (NCT01765582) assessed the efficacy of BEV plus FOLFOX/FOLFIRI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Hurwitz, Herbert I., Tan, Benjamin R., Reeves, James A., Xiong, Henry, Somer, Brad, Lenz, Heinz‐Josef, Hochster, Howard S., Scappaticci, Frank, Palma, John F., Price, Richard, Lee, John J., Nicholas, Alan, Sommer, Nicolas, Bendell, Johanna
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656450/
https://ncbi.nlm.nih.gov/pubmed/30552157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0344
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados